Boston Partners
GSK icon

Boston Partners’s GSK GSK Stock Holding History

Boston Partners’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-48,975
Closed -$2.19M – 652
2021
Q1 		$2.19M Sell
48,975
-4,395,163
-99% -$199M ﹤0.01% 473
2020
Q4 		$204M Sell
4,444,138
-189,484
-4% -$8.7M 0.32% 99
2020
Q3 		$218M Sell
4,633,622
-222,796
-5% -$11.2M 0.4% 84
2020
Q2 		$248M Sell
4,856,418
-3,349,856
-41% -$172M 0.45% 73
2020
Q1 		$389M Buy
8,206,274
+1,658,822
+25% +$88.5M 0.77% 35
2019
Q4 		$385M Buy
6,547,452
+5,409,216
+475% +$301M 0.51% 65
2019
Q3 		$60.8M Sell
1,138,236
-60,972
-5% -$3.14M 0.08% 228
2019
Q2 		$60M Sell
1,199,208
-65,866
-5% -$3.31M 0.08% 225
2019
Q1 		$66.1M Sell
1,265,074
-100,727
-7% -$5.03M 0.09% 218
2018
Q4 		$65.2M Buy
+1,365,801
New +$67.3M 0.09% 214

Other funds holding GSK

Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Hotchkis & Wiley Capital Management
Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BCIM
Black Creek Investment Management Toronto, Ontario, Canada $1.86B AUM 15.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Boston Partners's GSK Position: Q2 2021 in Review

Boston Partners sold out of GSK (GSK) in Q2 2021, closing a stake of 48,975 shares — an estimated $2.19M sold.

Boston Partners first reported a position in GSK in Q4 2018 and held it in 10 quarters. The position peaked at $389M in Q1 2020. 798 funds tracked by Wall St. Rank hold GSK as of Q2 2021.

  • Boston Partners reported no remaining GSK position as of Q2 2021 after selling out during the quarter.
  • Boston Partners sold 48,975 GSK shares in Q2 2021, an estimated $2.19M.
  • Boston Partners first reported a position in GSK in Q4 2018 and held it in 10 quarters.
  • Boston Partners's GSK position peaked at $389M in Q1 2020.
  • 798 funds tracked by Wall St. Rank held GSK as of Q2 2021.

Based on Boston Partners's 13F filing for Q2 2021, filed 12 Aug 2021.